<DOC>
	<DOCNO>NCT00225784</DOCNO>
	<brief_summary>This study design establish safety efficacy combination Erbitux ( cetuximab ) /Gemzar ( gemcitabine ) /radiation patient pancreatic cancer .</brief_summary>
	<brief_title>Cetuximab , Radiotherapy Twice Weekly Gemcitabine Treat Pancreatic Cancer</brief_title>
	<detailed_description>The study treatment protocol - Loading dose Cetuximab 400 mg/m2 - Weekly Cetuximab 250 mg/m2 - Bi-weekly Gemcitabine 50 mg/m2 - Daily Radiation 28 fraction - CT scan four week completion treatment - Evaluation surgeon resectability</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologic proof pancreatic adenocarcinoma Clinical stage I , II , III disease Radiographically measurable disease Tumor tissue epidermal growth factor receptor ( EGFR ) status immunohistochemistry Signed protocol consent Karnofsky performance status least 70 % Age &gt; = 18 year Patients must either child bear potential negative pregnancy test within 72 hour treatment . Absolute neutrophil count ( ANC ) &gt; 1500 ; platelet &gt; 100,000/ul . Creatinine &lt; 1.5 x upper limit normal ( ULN ) Bilirubin &lt; 1.5 x ULN ; AST &lt; 2.5 x ULN . Acute hepatitis know HIV Active uncontrolled infection Significant history cardiac disease Prior therapy affect target EGF pathway Prior severe infusion reaction monoclonal antibody Any concurrent chemotherapy indicate study protocol investigational agent Any previous chemotherapy abdominal pelvic radiotherapy No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , malignancy patient disease free five year . Any severe preexisting medical psychiatric condition , , opinion attend physician , interfere safe appropriate treatment followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Stage I , II , III pancreatic adenocarcinoma</keyword>
	<keyword>Radiographically measurable disease</keyword>
</DOC>